224 related articles for article (PubMed ID: 29203182)
1. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
von Delft A; Donnison TA; Lourenço J; Hutchings C; Mullarkey CE; Brown A; Pybus OG; Klenerman P; Chinnakannan S; Barnes E
Vaccine; 2018 Jan; 36(2):313-321. PubMed ID: 29203182
[TBL] [Abstract][Full Text] [Related]
2. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.
Donnison T; von Delft A; Brown A; Swadling L; Hutchings C; Hanke T; Chinnakannan S; Barnes E
Vaccine; 2020 Jul; 38(32):5036-5048. PubMed ID: 32532545
[TBL] [Abstract][Full Text] [Related]
3. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943
[TBL] [Abstract][Full Text] [Related]
4. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Hartnell F; Brown A; Capone S; Kopycinski J; Bliss C; Makvandi-Nejad S; Swadling L; Ghaffari E; Cicconi P; Del Sorbo M; Sbrocchi R; Esposito I; Vassilev V; Marriott P; Gardiner CM; Bannan C; Bergin C; Hoffmann M; Turner B; Nicosia A; Folgori A; Hanke T; Barnes E; Dorrell L
Front Immunol; 2018; 9():3175. PubMed ID: 30713538
[No Abstract] [Full Text] [Related]
5. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
6. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.
Kelly C; Swadling L; Brown A; Capone S; Folgori A; Salio M; Klenerman P; Barnes E
Eur J Immunol; 2015 Jan; 45(1):309-16. PubMed ID: 25263407
[TBL] [Abstract][Full Text] [Related]
8. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
[TBL] [Abstract][Full Text] [Related]
9. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
[TBL] [Abstract][Full Text] [Related]
10. Adenoviruses vectored hepatitis C virus vaccine cocktails induce broadly specific immune responses against multi-genotypic HCV in mice.
Luo S; Zhang P; Wang Y; Huang Y; Ma X; Deng Q; Zou P; Wang C; Zhang L; Li Y; Fu Y; Li T; Li C
Biomed Pharmacother; 2024 Jan; 170():115901. PubMed ID: 38056238
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
Kelly C; Swadling L; Capone S; Brown A; Richardson R; Halliday J; von Delft A; Oo Y; Mutimer D; Kurioka A; Hartnell F; Collier J; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Di Marco S; Siani L; Traboni C; Hill AV; Colloca S; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Hepatology; 2016 May; 63(5):1455-70. PubMed ID: 26474390
[TBL] [Abstract][Full Text] [Related]
12. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.
Wijesundara DK; Gummow J; Li Y; Yu W; Quah BJ; Ranasinghe C; Torresi J; Gowans EJ; Grubor-Bauk B
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437963
[TBL] [Abstract][Full Text] [Related]
13. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.
Barnes E; Folgori A; Capone S; Swadling L; Aston S; Kurioka A; Meyer J; Huddart R; Smith K; Townsend R; Brown A; Antrobus R; Ammendola V; Naddeo M; O'Hara G; Willberg C; Harrison A; Grazioli F; Esposito ML; Siani L; Traboni C; Oo Y; Adams D; Hill A; Colloca S; Nicosia A; Cortese R; Klenerman P
Sci Transl Med; 2012 Jan; 4(115):115ra1. PubMed ID: 22218690
[TBL] [Abstract][Full Text] [Related]
14. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
von Delft A; Humphreys IS; Brown A; Pfafferott K; Lucas M; Klenerman P; Lauer GM; Cox AL; Gaudieri S; Barnes E
Gut; 2016 Jan; 65(1):112-23. PubMed ID: 26092843
[TBL] [Abstract][Full Text] [Related]
15. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
16. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
17. Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development.
Cheng C; Wang L; Ko SY; Kong WP; Schmidt SD; Gall JGD; Colloca S; Seder RA; Mascola JR; Nabel GJ
Vaccine; 2015 Dec; 33(51):7344-7351. PubMed ID: 26514419
[TBL] [Abstract][Full Text] [Related]
18. Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.
Walker A; Skibbe K; Steinmann E; Pfaender S; Kuntzen T; Megger DA; Groten S; Sitek B; Lauer GM; Kim AY; Pietschmann T; Allen TM; Timm J
J Virol; 2016 Jan; 90(1):33-42. PubMed ID: 26446603
[TBL] [Abstract][Full Text] [Related]
19. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
